Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY686017 · 2 trials · 2 indications
The Alcohol Timeline Followback (TLFB) is used in calculating the percent reduction in heavy drinking days. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day during last 4 weeks. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| LY686017 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY686017 | DRUG | 50 milligrams (mg) daily by oral route for 12 weeks |
| Placebo | DRUG | Daily by oral route for 12 weeks |
| paroxetine | DRUG | - |
Inclusion Criteria: * Have Alcohol Dependence. * Are men or women who are ambulatory outpatients between 21 to 65 years of age (inclusive) showing evidence of living in a non-custodial stable residence and with no plans to move during the next 5 months. * Females of childbearing potential (not surg...
LY686017 is an investigational small molecule being studied for the treatment of alcohol dependence and social phobia, also known as social anxiety disorder. It is being developed by Eli Lilly and Company for use in psychiatry. The drug is currently in Phase 2 clinical development and is not approved by the FDA.
LY686017 is a small molecule developed by Eli Lilly and Company. Its specific molecular target has not been disclosed in available information. The drug is being investigated for its effects on alcohol dependence and social phobia, but the exact mechanism of action is not publicly detailed.
LY686017 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 2 clinical trials for alcohol dependence and social phobia.
LY686017 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 2 trials have been completed, one for social phobia and one for alcohol dependence, but the drug is not yet available commercially.
LY686017 has been studied in two completed Phase 2 clinical trials. NCT00191022 compared LY686017 with a marketed drug in 185 patients with social phobia in the United States. NCT00805441 studied LY686017 in 190 patients with alcohol dependence in the United States. Both trials were randomized, double-blind, and placebo-controlled.
LY686017 is an investigational compound with no alternative names listed in available information. It is being developed by Eli Lilly and Company for alcohol dependence and social phobia. As a Phase 2 investigational drug, it is not yet marketed under any brand name.